Phase I/II clinical trial of gene therapy for hormone refractory metastatic prostate cancer

被引：0
|
作者：
Gotoh, A [1 ]
Terao, S [1 ]
Shirakawa, T [1 ]
机构：
[1] Kobe Univ, Sch Med, Int Ctr Med Res & Treatment, Kobe, Hyogo 6500017, Japan
来源：
JOURNAL OF GENE MEDICINE | 2006年 / 8卷 / 03期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
引用
收藏
页码：371 / 372
页数：2
相关论文
共 50 条
  • [41] Phase II study of intravenous vinorelbine plus hormone therapy in hormone-refractory prostate cancer
    不详
    EUROPEAN UROLOGY SUPPLEMENTS, 2006, 5 (02) : 95 - 95
  • [42] Lycopene: a novel drug therapy in hormone refractory metastatic prostate cancer
    Ansari, MS
    Gupta, NP
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2004, 22 (05) : 415 - 420
  • [43] Review of phase II hormone refractory prostate cancer trials
    Murphy, GP
    UROLOGY, 1999, 54 (6A) : 19 - 21
  • [44] Treatment of hormone refractory prostate cancer patients by vaccination with autologous dendritic cells pulsed with recombinant prostate specific membrane antigen: A Phase I/II clinical trial
    Elgamal, AAA
    Boynton, A
    Bosch, M
    Salgaller, M
    Lodge, PA
    Shankar, G
    Belldegrun, A
    Logothetis, C
    Papandreou, C
    JOURNAL OF UROLOGY, 2002, 167 (04): : 306 - 306
  • [45] Vinorelbine and prednisone in older cancer patients with hormone-refractory metastatic prostate cancer - A phase II study
    Tralongo, P
    Bollina, R
    Aiello, R
    Di Mari, A
    Moruzzi, G
    Beretta, G
    Mauceri, G
    Conti, G
    TUMORI JOURNAL, 2003, 89 (01): : 26 - 30
  • [46] Phase II Trial of Eribulin in Patients With Metastatic Hormone Refractory Prostate Cancer A Trial of the ECOG-ACRIN Cancer Research Group (E5805)
    Stein, Mark N.
    Chen, Yu-Hui
    Carducci, Michael A.
    Hudes, Gary R.
    Lerma, Pauline M.
    Tan, Winston W.
    Dalune, Robert
    Rowland, Kendrith M.
    Kuzel, Timothy M.
    DiPaola, Robert S.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2019, 42 (04): : 375 - 381
  • [47] A phase II trial of CI-958 in patients with hormone-refractory prostate cancer
    Paul V. Woolley
    Fuad S. Freiha
    David C. Smith
    Lynn Carlson
    Janie Hofacker
    Nancy Quinn
    William Grove
    Donald L. Trump
    Cancer Chemotherapy and Pharmacology, 1999, 44 : 511 - 517
  • [48] Atrasentan delayed PSA progression in a phase II trial of men with hormone refractory prostate cancer
    Schulman, C
    Nelson, JB
    Weinberg, MA
    Humerickhouse, RA
    Schmitt, JL
    Nabulsi, AA
    JOURNAL OF UROLOGY, 2002, 167 (04): : 176 - 176
  • [49] A phase II trial of CI-958 in patients with hormone-refractory prostate cancer
    Woolley, PV
    Freiha, FS
    Smith, DC
    Carlson, L
    Hofacker, J
    Quinn, N
    Grove, W
    Trump, DL
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1999, 44 (06) : 511 - 517
  • [50] Phase II trial of weekly docetaxel, zoledronic acid and selenium for hormone refractory prostate cancer
    Kattan, J. G.
    Ghosn, M.
    Chahine, G.
    Saroufim, A.
    Nasr, F.
    Farhat, F. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345